The Canadian Nephrology Trials Network would like to acknowledge and congratulate their funding partner Can-SOLVE CKD Network on Phase 2 funding announcement. Can-SOLVE CKD will receive $3.75 million in new funding from CIHR matched by more than $8 million raised through the generous support of more than 60 partners.
The CNTN is thrilled about the investment being made by CIHR and Can-SOLVE CKD’s partner funders. Our organization is excited to continue our work towards improving the design, implementation and delivery of nephrology clinical trials in Canada.
CNTN Executive Co-Chairs Karthik Tennankore, François Madore, Hans Vorster, Dwight Sparkes
Can-SOLVE CKD Phase 2 is focused on mobilizing the findings of projects launched during the network’s first five years. Read the full network statement here: